Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 1/20 | 0.55 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.43 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.43 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.43 |
| ▸ | DGKA | P23743 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | GMNN | O75496 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | CETP | P11597 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | CXCR5 | P32302 | 2/20 | 0.42 |
| ▸ | CCR6 | P51684 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16086048 | 1.00 | ALDH1A1 (0.55) | ALDH1A1CNR1CNR2LPAR1LPAR2 | |
| SCHEMBL28992552 | 1.00 | ALDH1A1 (0.55) | ALDH1A1CNR1CNR2LPAR1LPAR2 | |
| SCHEMBL7591414 | 1.00 | ALDH1A1 (0.55) | ALDH1A1CNR1CNR2LPAR1LPAR2 | |
| SCHEMBL28992543 | 1.00 | ALDH1A1 (0.55) | ALDH1A1CNR1CNR2LPAR1LPAR2 | |
| SCHEMBL1735177 | 1.00 | ALDH1A1 (0.55) | ALDH1A1CNR1CNR2LPAR1LPAR2 | |
| Ethylene Glycol SCHEMBL26618285 | 0.98 | ALDH1A1 (0.54) | ALDH1A1CNR1CNR2LPAR1LPAR2 | |
| SCHEMBL16208869 | 0.96 | ALDH1A1 (0.62) | ALDH1A1CNR1CNR2 | |
| Ethylene Glycol SCHEMBL26618260 | 0.94 | ALDH1A1 (0.61) | ALDH1A1CNR1CNR2 | |
| SCHEMBL3892979 | 0.94 | ALDH1A1 (0.64) | ALDH1A1CNR1CNR2 | |
| SCHEMBL11459958 | 0.94 | ALDH1A1 (0.55) | ALDH1A1CNR1CNR2LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030229037-A1 | Novel cationic amphiphiles | MASSING ULRICH (DE) | 2003-12-11 | — | — | US | claimed |
| EP-1261620-A2 | CATIONIC AMPHIPHILES FOR USE IN NUCLEIC ACID TRANSFECTION | Roche Diagnostics Corporation (US) | 2002-12-04 | — | — | EP | claimed |
| WO-2001057064-A2 | CATIONIC AMPHIPHILES FOR USE IN NUCLEIC ACID TRANSFECTION | ROCHE DIAGNOSTICS CORPORATION (US) | 2001-08-09 | — | — | WO | claimed |
| EP-2976351-B1 | LIPOHILLIC OLIGONUCLEOTIDE ANALOGS | MILTENYI BIOTEC GMBH (DE) | 2018-02-21 | — | — | EP | disclosed |
| US-9803198-B2 | Lipohillic oligonucleotide analogs | MILTENYI BIOTEC, GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| EP-2976351-A1 | LIPOHILLIC OLIGONUCLEOTIDE ANALOGS | Miltenyi Biotec GmbH (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-20160017325-A1 | LIPOHILLIC OLIGONUCLEOTIDE ANALOGS | MILTENYI BIOTEC GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| WO-2014147095-A1 | LIPOHILLIC OLIGONUCLEOTIDE ANALOGS | MILTENYI BIOTEC GMBH (DE) | 2014-09-25 | — | — | WO | disclosed |
| EP-2781523-A1 | Lipophilic oligonucleotide analogs | Miltenyi Biotec GmbH (DE) | 2014-09-24 | — | — | EP | disclosed |
| US-20030229037-A1 | Novel cationic amphiphiles | MASSING ULRICH (DE) | 2003-12-11 | — | — | US | disclosed |
| EP-1261620-A2 | CATIONIC AMPHIPHILES FOR USE IN NUCLEIC ACID TRANSFECTION | Roche Diagnostics Corporation (US) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001057064-A2 | CATIONIC AMPHIPHILES FOR USE IN NUCLEIC ACID TRANSFECTION | ROCHE DIAGNOSTICS CORPORATION (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229037-A1 | Novel cationic amphiphiles | ABHD16A, APMAP, ABCB4 | ALDH1A1 4355/4885CNR1 3587/4885CNR2 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.